A study with data from nearly 14,000 patients with RA showed that exposure-adjusted event rates of HZ were highest for tsDMARDs. When data were adjusted for age, sex and glucocorticoids and weighted with inverse probability weights, tsDMARDs, anti-TNF-α treatment and B-cell-targeted therapy showed a significantly higher risk for HZ compared with conventional synthetic DMARDs.
The general practitioner recommends staying on the anti-TNF-α treatment for now but encourages the patient to speak with her rheumatologist about other treatment options that are available. The general practitioner tells the patient that the RA itself may have also contributed to her increased risk for HZ.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Heidi Moawad. Skill Checkup: A 40-Year-Old Woman With Rheumatoid Arthritis Has Fever, Headache, Photophobia and Painful, Burning Rash - Medscape - May 08, 2023.
Comments